Rituximab Therapy for Refractory Thrombotic Thrombocytopenic Purpura
- 1 May 2002
- journal article
- case report
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 28 (3) , 385-391
- https://doi.org/10.1006/bcmd.2002.0522
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic PurpuraJournal of Biological Chemistry, 2001
- Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpuraNature, 2001
- A Novel Human Metalloprotease Synthesized in the Liver and Secreted into the Blood: Possibly, the von Willebrand Factor--Cleaving Protease?The Journal of Biochemistry, 2001
- Purification of human von Willebrand factor–cleaving protease and its identification as a new member of the metalloproteinase familyBlood, 2001
- Partial amino acid sequence of purified von Willebrand factor–cleaving proteaseBlood, 2001
- Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic PurpuraAnnals of Internal Medicine, 2000
- IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using RituximabNeurology, 1999
- Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1998
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 1998
- Rituxan in the Treatment of Cold Agglutinin DiseaseBlood, 1998